Canada Pension Plan Investment Board Takes $1.12 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Canada Pension Plan Investment Board acquired a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 35,200 shares of the company's stock, valued at approximately $1,123,000.

A number of other large investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after acquiring an additional 758 shares during the period. Signaturefd LLC boosted its stake in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after buying an additional 918 shares in the last quarter. US Bancorp DE grew its holdings in Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after acquiring an additional 1,327 shares during the period. Covestor Ltd raised its position in Apellis Pharmaceuticals by 1,819.2% in the fourth quarter. Covestor Ltd now owns 3,992 shares of the company's stock worth $127,000 after acquiring an additional 3,784 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Apellis Pharmaceuticals by 89.0% during the 4th quarter. Russell Investments Group Ltd. now owns 6,107 shares of the company's stock worth $195,000 after purchasing an additional 2,876 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Trading Up 5.5 %

Shares of APLS stock traded up $1.00 during trading hours on Wednesday, hitting $19.21. 2,626,705 shares of the company were exchanged, compared to its average volume of 2,159,555. The firm has a fifty day moving average of $22.29 and a 200 day moving average of $27.53. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.98 and a 1 year high of $49.06. The firm has a market cap of $2.41 billion, a PE ratio of -9.46 and a beta of 0.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. During the same quarter in the prior year, the business posted ($0.73) earnings per share. Apellis Pharmaceuticals's revenue for the quarter was up 45.2% compared to the same quarter last year. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the completion of the sale, the general counsel now directly owns 138,730 shares in the company, valued at $3,482,123. This represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 6,115 shares of company stock valued at $154,684. 6.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

APLS has been the topic of a number of research analyst reports. Wedbush decreased their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Scotiabank lifted their price target on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research note on Wednesday, April 2nd. The Goldman Sachs Group lowered their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, Cantor Fitzgerald assumed coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday. They set an "overweight" rating and a $44.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $45.28.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).